TradingView report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Why OSUR Stock dropped -12.31% Today — RQD Quant Desk Flash
OraSure Technologies Inc. (OSUR) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OSUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, OraSure Technologies Inc. (NASDAQ: OSUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.46 (-12.31% 1D, market cap $271.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 4/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OSUR ranks #757 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OSUR compare to INFU and ANIK in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), OSUR carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 41.9%, and ROIC of -35.0%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and ANIK (Anika Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -10.2%, cap $280.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OSUR?
▼
Per OSUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001116463), OraSure Technologies Inc. generated $115.0M in revenue (-38.1% YoY), -$68.7M in net income, and -$53.2M in free cash flow against $403.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±9.5% realized swing band)
FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 51.3 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a OSUR Turnaround Squeeze
While OSUR currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.76) and Max Pain ($3.63) forces dealer call-delta covering toward $4.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why OSUR Stock dropped -12.31% Today — RQD Quant Desk Flash
OraSure Technologies Inc. (OSUR) dropped -12.31% to $3.46, trading at 55% of its 52-week range ($2.08 – $4.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 55% of its 52-week range ($2.08 – $4.58) with RSI-14 at 51.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.5% around $3.46 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 41.9% gross margin and $0 annual free cash flow.
Yahoo! Finance Canada report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Admirals report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Collaboration will bring diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementationBETHLEHEM, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.,
BETHLEHEM, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its third quarter 2026 financial results on Monday, November 9, 2026, after the market close
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OSUR)
- ✓Walkthrough of OSUR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
OSUR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -38.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OSUR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OSUR. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OSUR)
1. Head-to-Head Health Care Peer Comparison (OSUR vs. INFU, ANIK, TMCI, PROF)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, OraSure Technologies Inc. (OSUR) ranks #757 by composite RQD confidence (31/100, grade E) and #526 by equity capitalization ($271.7M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with OSUR at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OSUR
ACTIVE
OraSure Technologies Inc. | E | 31/100 | — | 41.9% | -35.0% | -12.31% | $271.7M | Benchmark Subject |
| INFU InfuSystems Holdings Inc. | B+ | 77/100 | 43.4x | 56.0% | 12.8% | -1.63% | $280.2M | /infu-vs-osur → |
| ANIK Anika Therapeutics Inc. | D+ | 53/100 | — | 56.6% | -10.2% | -7.35% | $280.4M | /anik-vs-osur → |
| TMCI Treace Medical Concepts Inc. | D- | 36/100 | — | 79.8% | -32.4% | -3.61% | $288.1M | /tmci-vs-osur → |
| PROF Profound Medical Corp. | D- | 40/100 | — | 70.8% | -35.0% | +2.44% | $240.0M | /prof-vs-osur → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001116463 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), OraSure Technologies Inc. (OSUR) reported GAAP revenue of $115.0M (-38.1% vs. FY2024 revenue of $185.8M , and -71.6% cumulative change since FY2023) , GAAP net income of -$68.7M, operating cash flow of -$49.0M, and free cash flow of -$53.2M (-325.7% YoY). On the balance sheet, OSUR closed FY2025 with $403.2M in total assets against $0 in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $115.0M | -$68.7M | -$49.0M | -$53.2M | $403.2M | — |
| FY2024 (FY) | 2024-12-31 | $185.8M | -$19.5M | $27.4M | $23.6M | $479.7M | — |
| FY2023 (FY) | 2023-12-31 | $405.5M | $53.7M | $141.6M | $141.6M | — | — |
3. OSUR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OSUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, OraSure Technologies Inc. (NASDAQ: OSUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.46 (-12.31% 1D, market cap $271.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 4/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OSUR ranks #757 in composite RQD confidence.
How does OSUR compare to INFU and ANIK in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), OSUR carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 41.9%, and ROIC of -35.0%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and ANIK (Anika Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -10.2%, cap $280.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OSUR?
Per OSUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001116463), OraSure Technologies Inc. generated $115.0M in revenue (-38.1% YoY), -$68.7M in net income, and -$53.2M in free cash flow against $403.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OSUR trading relative to its 50-day, 200-day, and 52-week technical levels?
OSUR last traded at $3.46 (-12.31% on volume of 861,642 shares), positioning the stock -7.98% below its 50-day simple moving average ($3.76) and -1.98% below its 200-day simple moving average ($3.53). Across its 52-week range of $2.08 to $4.58, OSUR sits at the 55.2% percentile with a 14-day RSI of 51.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($3.13 to $3.79).
OSUR — OraSure Technologies Inc.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
OraSure Technologies Inc. (OSUR) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.46 (-12.31% 1D, market capitalization $271.7M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 41.9%, operating margin of -60.0%, and free cash flow yield of -18.91%.
- Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (4/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.47, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
OraSure Technologies Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry (per the company profile). The profile does not describe its specific products, customers, or revenue model; those details are — The company's revenue is reported in the financials section, with FY 2025 revenue of $115.0M (). Gross margin is 41.9% (per the market data section).
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OraSure Technologies Inc. (OSUR) reported $115.0M in annual revenue (up from $185.8M in FY2024, -38.1% YoY) and -$68.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($405.5M revenue, $53.7M net income) through FY2025, OSUR scaled operating cash flow to -$49.0M and free cash flow to -$53.2M, backed by $403.2M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -18.91% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $2.08 – $4.58 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical/Dental Instruments (Health Care), OSUR carries a macro regime beta of 1.00 and gross margin of 41.9%.
- Key Question #1: Can OSUR sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $115.0M and free cash flow of -$53.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is OSUR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
OSUR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for OraSure Technologies Inc. (OSUR) • Click "Debate This Headline" to argue it in the Roar Pit below
TradingView report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Admirals report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering OraSure Technologies Inc. (OSUR) market action, institutional positioning, and fundamental catalysts.
OSUR Bull vs. Bear Conversation Board — What's Your Call at $3.46?
Institutional accumulation and options positioning (15 / 20 whale flow pillar) remain the strongest signal despite weak fundamentals.
Don't sleep on OSUR's setup in Health Care. Institutional accumulation and options positioning (15 / 20 whale flow pillar) remain the strongest signal despite weak fundamentals.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.
@AlphaFlow_Cap Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.94 and keeping dry powder in case we test $3.66.
ROIC of -35% and FCF yield of -18.91% show the cash engine is not generating returns, with Piotroski F at 3/9.
Sitting on the sidelines or leaning short OSUR above $3.94. ROIC of -35% and FCF yield of -18.91% show the cash engine is not generating returns, with Piotroski F at 3/9.. Until Fundamental Cash Engine (6/20) and FCF yield (-18.91%) inflect higher, upside is capped near $4.58.